George Bakris to Glucose
This is a "connection" page, showing publications George Bakris has written about Glucose.
Connection Strength
1.917
-
Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol. 2016 Mar; 12(3):128-9.
Score: 0.443
-
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009 Jun; 75(12):1272-1277.
Score: 0.278
-
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes Endocrinol. 2023 Dec; 11(12):892-894.
Score: 0.192
-
The changing trajectory of diabetic kidney disease. Curr Opin Nephrol Hypertens. 2023 01 01; 32(1):98-102.
Score: 0.177
-
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 11; 102(5):974-989.
Score: 0.177
-
Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Curr Hypertens Rep. 2019 02 12; 21(2):12.
Score: 0.137
-
Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. J Clin Hypertens (Greenwich). 2018 04; 20(4):625-626.
Score: 0.129
-
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133.
Score: 0.127
-
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 06; 11(3).
Score: 0.046
-
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023 08; 25(8):2151-2162.
Score: 0.046
-
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022 12 01; 45(12):2991-2998.
Score: 0.045
-
Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022 08 01; 28(8):e301-e307.
Score: 0.044
-
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762.
Score: 0.039
-
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617.
Score: 0.037